Open Government Portal

Found 10 records similar to Declaring an attempt at negotiating a voluntary licence under Canada's Access to Medicines Regime

Federal

Within 15 days of the day on which the compulsory licence was granted or the supply agreement was signed, whichever is later, the pharmaceutical company must complete and submit to the patent holder and the Commissioner of Patents a "Solemn or Statutory Declaration Under Paragraph 21.16(1)(b) of the Patent Act".

Last Updated: Sep. 17, 2020
Date Published: Apr. 28, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, declaring monetary value and units sold, compulsory licence, supply agreement
Federal

The pharmaceutical company must complete and submit to the Commissioner of Patents one of the forms listed below. The company should choose the form that corresponds to the schedule on which the importing country appears, as well as the patent status of the pharmaceutical product in that country.

Last Updated: Sep. 17, 2020
Date Published: Apr. 28, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, declare identity and patent status of pharmaceutical product, pharmaceutical company, Commissioner of Patents.
Federal

Governments can override patent rights when necessary. In such instances, the government authorizes a third party to use the patented invention without the patent holder's permission. This authorization comes in the form of a compulsory licence.

Last Updated: Sep. 17, 2020
Date Published: Mar. 29, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, compulsory licences, override patent rights, authorizes a third party, patented invention, patent holder's permission.
Federal

The company must submit the application package to the Commissioner of Patents at the Canadian Intellectual Property Office (CIPO).

Last Updated: Sep. 17, 2020
Date Published: Apr. 28, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, submit the application package, the Commissioner of Patents at the Canadian Intellectual Property Office.
Federal

To participate in the Regime, an eligible importing country must declare that it has insufficient or no pharmaceutical manufacturing capacity in relation to the specific product it is requesting. It is up to each country to determine for itself the level of its manufacturing capacity.

Last Updated: Sep. 17, 2020
Date Published: Mar. 29, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, manufacturing capacity, eligible importing country, insufficient or no pharmaceutical manufacturing capacity.
Federal

To participate in the Regime, a pharmaceutical company must enter into a sales agreement with an eligible importing country for the purchase of a specified amount of an eligible product listed on Schedule 1. A pharmaceutical company must also submit an application for authorization to Canada's Commissioner of Patents. Once the authorization or compulsory licence is issued, there are additional terms and conditions that the company must meet and maintain.

Last Updated: Sep. 17, 2020
Date Published: Mar. 29, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Company requirements under Canada's Access to Medicines Regime, sales agreement, compulsory licence, eligible importing country, eligible product, application for authorization to Canada's Commissioner of Patents.
Federal

The patent holder may seek an order from the Federal Court of Canada to terminate a compulsory licence, if the patent holder can establish that any information in the application by the licence holder is inaccurate or that the licence holder has failed

Last Updated: Sep. 17, 2020
Date Published: Mar. 29, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, termination of authorization, terminate a compulsory licence, patent holder, Federal Court of Canada.
Federal

A pharmaceutical company that holds a compulsory licence under Canada's Access to Medicines Regime is required to pay royalties to the patent holder. The company must make payments within a prescribed amount of time and in accordance with a prescribed formula.

Last Updated: Sep. 17, 2020
Date Published: Apr. 28, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, company that holds a compulsory licence, patent holder, Royalty payments.
Federal

The legislation establishing Canada's Access to Medicines Regime contains a "Good Faith Clause" that provides patent holders with the right to challenge a compulsory licence in the Federal Court of Canada. A challenge can be mounted if the patent holder believes the licence is being used for predominantly commercial rather than humanitarian purposes.

Last Updated: Sep. 17, 2020
Date Published: Mar. 29, 2017
Organization: Health Canada
Formats: HTML
Keywords:  Canada's Access to Medicines Regime, Good faith clause, patent holders, right to challenge, compulsory licence.
Federal

This dataset contains a list of Significant or Commercial Discovery Declarations (SDD and CDD), on Frontier Lands under the CPRA, that the CER regulates. This list includes the declaration date, company, the field name and/or well name, CER area and sections identified.

Last Updated: Nov. 23, 2020
Date Published: Nov. 23, 2020
Organization: Canada Energy Regulator
Formats: CSV
Keywords:  Significant, Commercial, Discovery, Declaration, Declarations, Frontier, Lands, Geological, Well
Date modified: